白蛋白结合型紫杉醇治疗复发晚期非小细胞肺癌的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Albumin-bound Paclitaxel in the treatment of recurrent advanced non-small cell lung cancer.Methods A total of 40 patients with recurrent advanced non-small cell lung cancer treated in Jingjiang People′s Hospital from February 2018 to August 2020 were selected as the research subjects and divided into the study group(20 cases)and the control group(20 cases)according to random number table method.The control group received conventional Paclitaxel chemotherapy regimen,and the study group received Albumin-bound Paclitaxel treatment.The total effective rate,total incidence of adverse reactions and quality of life scores of two groups were compared.Results The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P＜0.05).The incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Before treatment,there was no significant difference in quality of life scores between the two groups(P＞0.05).After treatment,the quality of life scores of the two groups were higher than before treatment,and the study group was higher than the control group,the differences were statistically significant(P＜0.05).Conclusion Treatment with Albumin-bound Paclitaxel in patients with recurrent advanced non-small cell lung cancer has a better effect,which can improve clinical symptoms and quality of life,and has a higher safety,which is worthy of clinical promotion.

Key words： Albumin-bound Paclitaxel Retreatment Advanced non-small cell lung cancer Therapeutic effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HOU Juan
	CUI Li-hua
	WU Zhi-wei
	HUANG Yu-feng
	MA De

Cite this article:

HOU Juan,CUI Li-hua,WU Zhi-wei, et al. Clinical effect of Albumin-bound Paclitaxel in the treatment of recurrent advanced non-small cell lung cancer[J]. 中国当代医药, 2021, 28(17): 106-108.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I17/106

[1]	孙绍富.观察白蛋白结合型紫杉醇治疗复治晚期非小细胞肺癌的临床疗效[J].世界最新医学信息文摘（连续型电子期刊），2019，19（1）：31-32.
[2]	郎然，金建军，张彭辉，等.白蛋白结合型紫杉醇联合顺铂对非小细胞肺癌引起的恶性胸腔积液的疗效[J].广东医学，2018，39（15）：2369-2372，2376.
[3]	杨科，李峻岭，杜斌，等.白蛋白结合型紫杉醇二线及以上治疗晚期非小细胞肺癌的单臂、单中心探索性临床研究[J].中国临床药理学与治疗学，2019，24（11）：1281-1286.
[4]	张萍，陈明月，周志国.白蛋白结合型紫杉醇在晚期非小细胞肺癌中的研究进展[J].饮食保健，2019，6（34）：297-298.
[5]	孙学峰，丁培堃，王光锁.不同剂量胸腺肽联合白蛋白结合型紫杉醇+卡铂治疗局部晚期非小细胞肺癌的效果观察[J].基层医学论坛，2019，23（20）：2862-2863.
[6]	郭燕蓉.白蛋白结合型紫杉醇在晚期非小细胞肺癌治疗中的临床研究[J].医药前沿，2018，8（36）：392-393.
[7]	顾燕兰，孙钢，浦明之.单药白蛋白结合型紫杉醇治疗晚期非小细胞肺癌的疗效及安全性分析[J].癌症进展，2018，16（11）：1364-1367，1378.
[8]	卢家彬，郭金成，张冬梅.白蛋白结合型紫杉醇联合洛铂与顺铂治疗晚期非小细胞肺癌临床疗效比较[J].北方药学，2018，15（7）：112.
[9]	刘申吒，马德，侯娟.酪氨酸激酶抑制剂治疗耐药后的非小细胞肺癌的治疗方法分析[J].临床医药文献电子杂志，2019，6（74）：166-167.
[10]	萧剑军，董文静，彭杰文，等.白蛋白结合型紫杉醇单药三线治疗老年晚期非小细胞肺癌患者临床观察[J].肿瘤研究与临床，2018，30（1）：57-59.
[11]	晋发，付金平，文昱婷，等.白蛋白紫杉醇联合胸腺法新治疗老年无驱动基因突变晚期NSCLC 患者临床观察[J].中华肿瘤防治杂志，2020，27（12）：974-979.
[12]	罗居东，卢绪菁，周希法，等.白蛋白结合型紫杉醇治疗复治晚期非小细胞肺癌的临床观察[J].中华肿瘤防治杂志，2014，21（23）：1911-1913.
[13]	曹兴，方建惠.顺铂联合吉西他滨与联合白蛋白结合型紫杉醇治疗晚期非小细胞肺癌的效果及安全性对比[J].当代医药论丛，2020，18（16）：58-60.
[14]	高萌，呼群，李超.过表达富含半胱氨酸的酸性分泌蛋白对非小细胞肺癌细胞白蛋白结合型紫杉醇敏感性的影响[J].中国医药，2020，15（2）：221-225.
[15]	刘书齐.紫杉醇联合顺铂同步治疗非小细胞肺癌的效果分析[J].糖尿病天地，2020，17（8）：88.